Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.06 (+4.44%)
Close on Nov 17, 2026Market cap $1.43MP/E –Yield –
Transcode Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Transcode Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $17.44M, up 80.7% year over year. For fiscal 2025 it was $13.42M, up 38.3% from the year before. The highest annual figure on record is $13.42M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.42M | +38.3% |
| FY2024 | Dec 31, 2024 | $9.71M | -20.9% |
| FY2023 | Dec 31, 2023 | $12.26M | +19.9% |
| FY2022 | Dec 31, 2022 | $10.23M | +271.6% |
| FY2021 | Dec 31, 2021 | $2.75M | +868.1% |
| FY2020 | Dec 31, 2020 | $284.46K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.69M | +44.0% |
| Q1 FY2026 | Mar 31, 2026 | $5.11M | +130.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.48M | +50.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.16M | +157.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.57M | -16.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.22M | +26.2% |
| Q4 FY2024 | Dec 31, 2024 | $3.64M | +8.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.23M | -63.3% |
| Q2 FY2024 | Jun 30, 2024 | $3.08M | +3.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.76M | -32.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.36M | +25.2% |
| Q3 FY2023 | Sep 30, 2023 | $3.34M | +9.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.97M | +13.2% |
| Q1 FY2023 | Mar 31, 2023 | $2.59M | +37.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.69M | +109.0% |
| Q3 FY2022 | Sep 30, 2022 | $3.04M | +206.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.62M | +1137.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.88M | +613.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.29M | +746.7% |
| Q3 FY2021 | Sep 30, 2021 | $992.95K | +1741.0% |
| Q2 FY2021 | Jun 30, 2021 | $211.75K | +182.3% |
| Q1 FY2021 | Mar 31, 2021 | $263.76K | – |
| Q4 FY2020 | Dec 31, 2020 | $151.82K | – |
| Q3 FY2020 | Sep 30, 2020 | $53.94K | – |
| Q2 FY2020 | Jun 30, 2020 | $75.00K | – |
See a number that looks wrong?